The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.

Lybalvi, a combination of olanzapine and samidorphan, is an antipsychotic medication designed to treat specific mental health conditions in adults. Lybalvi was approved by the U.S. Food and Drug Administration (FDA) on May 28, 2021.

Kiniksa Pharmaceuticals International announced that it has begun enrolling participants for the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.

Sotorasib, marketed under the brand name Lumakras, is a medication designed to treat non-small cell lung cancer (NSCLC). Sotorasib was granted FDA approval on May 28, 2021.

AEON Biopharma revealed their intention to proceed with a crucial clinical development trial in cervical dystonia for their main product, ABP-450 (prabotulinumtoxinA) injection.

Myfembree is a combination oral medication containing estradiol, norethindrone, and relugolix. Myfembree was approved by the FDA on May 26, 2021.

Jul 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Pylarify was approved by the U.S. Food and Drug Administration (FDA) on May 26, 2021.

Jul 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved amivantamab (Rybrevant) on May 21, 2021.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

Pegcetacoplan (Empaveli) was approved by the U.S. Food and Drug Administration (FDA) on May 14, 2021, for the treatment of PNH.